Previous cardiovascular outcome trials (CVOTs) have demonstrated that sodium glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular and renal outcomes, including hospitalization for heart failure (HHF), in patients with type 2 diabetes and a high risk of cardiovascular events [1]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.